Clinical Trial

Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-003 Delivered by Intravenous Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab.
Trial Details
NCT Number NCT07751042
Lead Sponsor Strand Therapeutics Inc.
Conditions Advanced Solid Tumor
Enrollment 220 participants
Start Date 2026-06-30
Primary Completion 2030-07-17 (estimated)
Study Completion 2030-11-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-06